Horizon Pharma (HZNP) Tops Q3 EPS by 15c, Offers Guidance

Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results

-- Third-Quarter 2019 Net Sales of $335.5 Million Increased 3 Percent;
Third-Quarter 2019 GAAP Net Income of $18.2 Million; Adjusted EBITDA of $130.4 Million --

-- Record Quarterly Orphan and Rheumatology Segment Net Sales of $250.4 Million, an Increase
of 14 Percent; Segment Represents Approximately 75 Percent of Total Company Net Sales;
KRYSTEXXA® Third-Quarter 2019 Net Sales of $99.6 Million Increased 42 Percent --

-- Maintaining Full-Year 2019 Net Sales Guidance Range of $1.28 to $1.30 Billion;
Raising Midpoint of Full-Year 2019 Adjusted EBITDA Guidance; Range is Now
$465 Million to $475... More